Compare ING Groep NV (ING) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs ResMed Inc. — how do they compare? ING Groep NV trades at $33.09 (market cap $96.81B), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ING Groep NV is far larger — about 3× ResMed Inc.'s market cap, and ING Groep NV pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and ResMed Inc. for 51 Days on average.
| ING | RMD | |
|---|---|---|
Market Cap | $96.81B | $31.78B |
Volume | 2,635,505 | 1,128,382 |
Sector | Financials | Health |
52-Week High | $37.27 | $277.88 |
52-Week Low | $23.66 | $182.82 |
Typical Hold Time | 93 Days | 51 Days |
Enterprise Value | $236.31B | $31.14B |
Dividend Yield | 3.9% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING stock trades at $33.43, down 4.21% with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters with Q2 2026 EPS of $0.79 versus $0.75 expected. Revenue growth remains steady at $22.9B in 2025 with a robust 28.34% net margin. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations.
The stock presents a value opportunity with a reasonable P/E of 13.09 and strong profitability metrics, though negative cash flow trends and regulatory challenges in Australia warrant monitoring. Management's raised ROE target above 16% for 2027 signals confidence in continued operational improvement and strategic execution.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
